Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Deholl

Urology Hendersonville, NC Medical Doctor

NPI 1700971363 CMS profile 77054

1216 6Th Ave W, Hendersonville, NC 28739

Open in the dashboard

General payments

$10,240

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Deholl of Hendersonville, NC is reported in the CMS Open Payments database as having received $10,240 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2024 General $1,478 9
2023 General $2,290 36
2022 General $778 42
2021 General $917 53
2020 General $505 32
2019 General $4,249 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Deholl
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to John Deholl were reported at $22. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year John Deholl Urology median Middle half National median
2019 $4,249 $480 $147–$1,201 $163
2020 $505 $246 $87–$645 $114
2021 $917 $358 $111–$1,000 $132
2022 $778 $476 $143–$1,263 $149
2023 $2,290 $560 $168–$1,461 $160
2024 $1,478 $563 $170–$1,464 $164
2025 $22 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,131 4 payments
  2. PROCEPT BioRobotics Corporation $1,918 16 payments
  3. NeoTract Inc. $1,520 4 payments
  4. Axonics Modulation Technologies, Inc. $1,261 11 payments
  5. Janssen Biotech, Inc. $771 39 payments
  6. Astellas Pharma US Inc $624 34 payments
  7. Endo Pharmaceuticals Inc. $545 38 payments
  8. Teleflex LLC $203 4 payments
  9. Pfizer Inc. $187 11 payments
  10. AbbVie, Inc. $182 11 payments
  11. Other $897 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,458 201 payments
  2. Travel and Lodging $3,681 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,100 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM $2,131 4 payments
  2. UROLIFT $1,542 5 payments
  3. Axonics $1,233 9 payments
  4. Bulkamid $1,135 4 payments
  5. AQUABEAM ROBOTIC SYSTEM $1,118 12 payments
  6. AQUABEAM SYSTEM $801 4 payments
  7. ERLEADA $719 34 payments
  8. XIAFLEX $540 37 payments
  9. MYRBETRIQ $540 29 payments
  10. AVEED $525 36 payments
  11. Other $2,425 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,086

Median for Urology: 1,053

Drug cost

$548,207

Median for Urology: $101,464

Branded share of claims

39.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 17 $350,860
Myrbetriq Mirabegron Brand 194 $116,325
Gemtesa Vibegron Brand 55 $41,491
Elmiron Pentosan Polysulfate Sodium Brand 14 $22,754
Potassium Citrate Er Potassium Citrate Brand 58 $6,054
Tamsulosin Hcl Generic 391 $4,971
Finasteride Generic 111 $1,358
Solifenacin Succinate Generic 68 $1,345
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 44 $1,197
Estradiol Generic 11 $714

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$75,471

Medicare's payments for the services billed

Medicare patients

567

Average age 76

Services billed

1,186

92 women, 475 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 45%
Ischemic heart disease 28%
Cancer 25%
Chronic kidney disease 22%
Diabetes 21%
Atrial fibrillation 21%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record